Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FJPWA Calls For Resumption of Ryukaikon
February 7, 2011
- Takeda, MSD Call For Precautions on Similar Drug Names
February 7, 2011
- Meiji Seika, Fresenius Kabi Ally to Develop Anticancer Generics Business in Japan
February 7, 2011
- NBI's Mirapex Recommended for Approval
February 7, 2011
- Mochida Aims at Sales of ¥10 Bil. with Generics
February 7, 2011
- Making Whole of Japan Large Pharmaceutical Company: Prof. Nakamura
February 7, 2011
- Nichi-Iko to Raise ¥20 Bil. through Public Stock Offerings
February 7, 2011
- Pfizer Aims for Approval of 7 Products Each Year: President Umeda
February 7, 2011
- Gov't Rejects Court-Proposed Compromise in Iressa Lawsuits
February 7, 2011
- Torii Starts PIII Trial of Sublingual Desensitization Therapy for Cedar Pollinosis
February 7, 2011
- Dr Teshirogi Calls on Doctors to Cooperate to Obtain More Financial Resources for Healthcare
February 7, 2011
- MTPC Applies for MP-424 in Japan
February 7, 2011
- Takeda Begins PIII Trial of AMG 386 in Japan
February 7, 2011
- MTPC Shipped 4 Injectables without Conducting Necessary Quality Tests
February 7, 2011
- Novartis Applies for Canakinumab for CAPS
February 7, 2011
- Insight Obtained into Mechanism of Nerve Cell Protection Following Cerebral Infarction
February 7, 2011
- Top-4 Wholesalers Report Slow Price Settlement, Difficulty in Reducing Yakkasa
February 7, 2011
- Eisai Won't Seek Regulatory Approval for Eritoran in March
February 7, 2011
- Peretinoin Reduces Risk of HCC Recurrence or Death
February 7, 2011
- JACDS Calls on Its Members to Refrain from Offering Points for Dispensing Services
February 7, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…